Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II neoadjuvant chemotherapy and chemoradiation in locally advanced rectal cancer
2018-002095-40Phase 2Terminated
- Sponsor
- HM Hospitales
- Start
- Jan 2019
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of irinotecan liposome, irinotecan, oxaliplatin, folinic acid and fluorouracil in rectal cancer and locally advanced rectal cancer (LARC), sponsored by HM Hospitales. Primary endpoint: Clinical complete response rate. Started Jan 2019; status: terminated.
02
Drugs
irinotecan liposomeirinotecanoxaliplatinfolinic acidfluorouracil
03
Conditions
rectal cancerlocally advanced rectal cancer (LARC)
Beyond the preview
Go deeper on 2018-002095-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002095-40.